Pharma News

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation. ...

Pfizer has announced that the first participants have been dosed in a phase 3 clinical trial evaluating the efficacy, immunogenicity, safety and tolerability of its investigational quadrivalent mod...

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

Mallinckrodt plc (MNKPF) said that the U.S. Food and Drug Administration approved Terlivaz (terlipressin) for injection.

London: BA.4.6, a subvariant of the omicron COVID variant which has been quickly gaining traction in the US, is now confirmed to be spreading in the UK. 

Researchers from the Walter Reed Army Institute of Research (WRAIR) report the malaria vaccine FMP013 antigen and ALFQ adjuvant combination appears safe and immunogenic for adults in the first-in-h...

There was a 307 percent increase in new long COVID cases identified between 2020 and 2021, according to modeling the University of Washington’s Institute for Health Metrics and Evaluation (IMHE)...

aTyr Pharma received a Fast Track designation for its investigational candidate efzofitimod in the treatment of patients with systemic sclerosis-associated interstitial lung disease. ...

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatme...

Two FDA committees, the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee, will be reviewing Perrigo’s Opill (norgestrel tablets) fo...

Pfizer and BioNTech’s COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA’s human medicines committee, shortly after the panel gave its blessing ...

The FDA and EMA have accepted Pfizer’s New Drug Application (NDA) and Marketing Authorization Application (MAA) for ritlecitinib, both for adults and adolescents 12 years of age and older with al...